Facilitated DNA damage repair as an emerging therapeutic strategy for inflammatory and fibrotic diseases

Fibrosis is a common feature of many chronic inflammatory diseases across organs, including liver, lung, skin and heart and remains a major cause of morbidity and mortality worldwide. Despite diverse etiologies, fibrotic disorders share various hallmarks, including persistent inflammation, cellular senescence, fibroblast activation and an excessive buildup of extracellular matrix (ECM) that replaces the functional parenchyma. Current anti-fibrotic therapies primarily target downstream inflammatory or pro-fibrotic signalling pathways with limited efficacy regarding the reversal of the disease.¹

An emerging body of evidence indicates that persistent DNA damage drives chronic inflammation and fibrosis.^2,3 Metabolic stress and mitochondrial dysfunction result in the formation of elevated levels of reactive oxygen species (ROS), which generates oxidative DNA damage lesions, particularly 8-oxo-7,8-dihydroguanine (8-oxoG). When the load of DNA lesions exceeds the capacity of repair pathways, DNA damage response (DDR) signalling is activated, which promotes cellular senescence, stimulates pro-inflammatory signaling and activates fibroblasts, which jointly shape a pro-fibrotic microenvironment.^4,5 Importantly, these lesions are not limited to oxidized bases but also include bulky adducts, replication-associated lesions, DNA double-strand breaks and telomere-associated damage, which can similarly drive persistent DDR signaling and senescence.⁶

In this review, we summarize the role of DNA damage repair across organ systems, including the skin, liver, lung and cardiovascular system, with a focus on metabolic diseases and aging. We present nuclear and mitochondrial repair pathways and their integration with innate immune sensing and highlight emerging pharmacological approaches to provide repair directionality. Lastly, we discuss how facilitated DNA damage repair can emerge as an actionable strategy to counteract chronic inflammation and fibrosis.

The skin is continuously exposed to genotoxic stress, particularly ultraviolet (UV) radiation, environmental pollutants, and oxidative stress. As a result, epidermal and dermal cells accumulate a spectrum of DNA lesions, including cyclobutane pyrimidine dimers (CPDs), and oxidative base damage such as 8-oxoG. Upon efficient repair, skin injury remains transient. However, a dysfunctional response may result in the accumulation of persistent DNA damage and drive chronic inflammation, fibroblast activation, dermal thickening and ultimately cutaneous fibrosis.

In sustained DNA damage signalling, both inflammatory dermatitis and fibrotic skin disorders share a common upstream feature. UV-induced lesions activate ATR/ATM signalling, PARP1,⁷⁰ and p53, leading to keratinocyte cell-cycle arrest, apoptosis or senescence.⁷¹ Senescent keratinocytes and fibroblasts secrete cytokines, growth factors and matrix-modifying enzymes that remodel the dermal ECM. Over time, this SASP promotes fibroblast activation and collagen deposition, coupling epidermal DNA damage to dermal fibrosis.⁷² Oxidative DNA damage further amplifies these processes. 8-OxoG accumulation triggers BER, with OGG1-dependent repair intermediates contributing to the expression of pro-inflammatory genes when repair is incomplete. Importantly, the skin experiences repeated low-dose injury, making it particularly sensitive to cumulative repair inefficiency rather than acute failures.

The skin provides the clearest and most mature evidence that facilitating DNA repair is therapeutically beneficial. Topical delivery of DNA repair enzymes has been developed to accelerate lesion removal following UV exposure.⁷³ Liposome-encapsulated photolyase directly reverses CPDs, reduces UV-induced DNA damage, suppresses inflammatory responses and slows features of photoaging in both preclinical and clinical studies.^74,75 Similar effects have been reported for topical formulations containing T4 endonuclease V, which initiates repair of CPDs via the nucleotide excision repair pathway.⁷⁶ These interventions demonstrate that acceleration of lesion clearance attenuates downstream inflammation and tissue remodelling, even after successful DNA damage repair.

Beyond UV photolesions, oxidative DNA damage is abundant in chronically inflamed or aged skin. OGG1, NEIL1/2 and associated BER enzymes are expressed in keratinocytes and fibroblasts and their activity declines with age and chronic inflammation.^8,77 Reduced BER capacity correlates with increased oxidative damage burden, prolonged DNA damage response (DDR) signalling, and enhanced fibroblast activation. Further, impaired BER leads to persistent strand-break intermediates, PARP1 hyperactivation, NAD⁺ depletion and cellular dysfunction, processes strongly linked to fibrotic remodelling.^78,79

Telomeres are particularly vulnerable to oxidative stress and telomeric DNA damage repair is less efficient than in other parts of the chromosome. Accumulation of telomere-associated lesions drives replicative senescence in keratinocytes and fibroblasts, contributing to epidermal thinning, impaired regeneration, and dermal fibrosis.⁸⁰ Importantly, strategies that stabilize telomeres or enhance repair responses at telomeres mitigate skin aging and fibrotic responses. Recent studies employing TERT mRNA delivery or transient telomerase activation in the context of radiation-induced skin injury demonstrated improved tissue repair and reduced fibrotic remodelling.⁸¹

The dominant injury type in cutaneous fibrosis is chronic and cumulative due to environmental exposure, rather than being due to acute bursts of metabolic stress. This renders the skin a model for enhanced DNA repair, mainly due to limited proliferation compared to other organs. As such, in tissues subjected to repetitive low levels of genotoxic stress, facilitated DNA repair acts through reducing inflammation, minimizing senescence and limiting fibrotic remodelling. This stands in sharp contrast with acute injury mechanisms, where transient suppression of repair-linked inflammatory signalling may be beneficial.

The liver is continuously exposed to genotoxic stress arising from endogenous metabolic activity and exogenous insults. Common stressors include lipotoxicity in MASH, alcohol metabolism, various xenobiotics and hepatotropic viruses that all result in elevated formation of ROS.^82,83 As in other organs, persistent oxidative stress results in an increased load of 8-oxoG and other DNA damage lesions in the liver.^84,85 This results in cell-cycle arrest, apoptosis, or senescence, depending on injury severity and repair capacity. Senescent hepatocytes secrete pro-inflammatory cytokines and chemokines. This SASP amplifies immune cell recruitment and directly activates hepatic stellate cells (HSCs), thereby linking metabolic hepatocyte dysfunction to inflammation, stellate cell transdifferentiation and fibrotic ECM remodeling.

Senescence in the liver is also linked to the formation of polyploid hepatocytes and oxidative stress directly favors polyplodization in metabolic liver disease.⁸⁶ Polyploid hepatocytes are less proliferative and thus might confer protection against malignant transformation due to extensive DNA damage.⁸⁷ Polyploidization can thereby buffer against gene-inactivating mutations when DNA damage repair is overwhelmed.⁸⁸ Thus, polyploidization can maintain hepatocyte function while removing the damaged hepatocytes from the proliferative pool.

DNA glycosylases are important modulators of hepatic metabolism and the response to injury. Mice deficient in Neil1, Smug1 or Ogg1 exhibit hyperglycemia, hyperinsulinemia, impaired hepatic mitochondrial function and hepatic steatosis.^89–91 These results indicate that DNA glycosylases play important roles in hepatic homeostasis. These results are corroborated by previous experimental data showing that small molecule modulators of OGG1 that act as organocatalytic switches (ORCAs) to accelerate the repair of oxidative lesions could reduce fibrosis in ex vivo 3D liver cultures derived from MASH patients.⁹² In contrast to DNA glycosylases, PARP appears to be pro-inflammatory and pro-fibrotic.^93–95 Interestingly, these findings seem to contrast new results that demonstrate that increasing the hepatic NAD⁺ pool by inhibiting aminocarboxymuconate semialdehyde decarboxylase (ACMSD), a key factor in controlling NAD⁺ biosynthesis, ameliorates MASH and fibrosis phenotypes in various mouse models and human organoids.⁹⁶ Further research will be required to consolidate these different observations.

Mitochondrial dysfunction constitutes a central feature of chronic liver diseases⁹⁷ and modulation of mitochondrial metabolism constitutes a key target for emerging anti-fibrotic therapies.⁹⁸ Activation of cGAS–STING signaling in the liver triggers the activation of HSCs and the promotion of a pro-inflammatory milieu^99,100 and STING is upregulated in patients with metabolic liver disease.¹⁰¹ Notably however, other recent studies indicate that the cGAS–STING axis contributes to HSC senescence, which limits hepatic fibrosis.^102,103 The exact cause underlying these divergent findings is not clear but suggests that the cGAS–STING pathway could play complex context-dependent roles in hepatic inflammation and fibrosis.

In contrast, inflammasome activation has been consistently linked to hepatic inflammatory signaling and fibrosis. Knock-in of a dominant active Nlrp3 in myeloid cells or neutrophils resulted in severe liver inflammation, hepatocyte death and extensive fibrosis.^104,105 Inversely, the NLRP3 inhibitor MCC950 inhibited hepatic inflammation and fibrosis in a dietary mouse model of MASH.¹⁰⁶

Combined, the available data suggest that acceleration of DNA glycosylases has beneficial roles for hepatic metabolism, inflammation and fibrosis across model systems. In contrast, the available evidence is less consistent for the role of PARPs and cGAS–STING signaling.

The lung is continuously exposed to endogenous and exogenous genotoxic stress, including ROS produced during respiration, airborne pollutants, cigarette smoke, infections and mechanical strain. Consequently, epithelial cells, endothelial cells and resident immune cells accumulate DNA damage throughout life. Pulmonary fibrosis emerges when this damage is persistent, poorly repaired, or repeatedly reintroduced, resulting in chronic inflammation, epithelial dysfunction and progressive activation of fibroblasts and myofibroblasts.¹⁰⁷

Both experimental and clinical studies demonstrate that DNA damage accumulates in fibrotic lung tissue. Elevated levels of oxidative DNA lesions, notably 8-oxoG, but also persistent γH2AX foci and activation of DDR pathways are observed in lung epithelial cells from patients with idiopathic pulmonary fibrosis (IPF) and in bleomycin-induced fibrosis models.^108,109 These signals trigger apoptosis or senescence in alveolar epithelial cells, impair epithelial regeneration, and generate a pro-fibrotic microenvironment characterized by high levels of TGF-β, IL-1β and other inflammatory mediators.¹¹⁰ Importantly, epithelial senescence has emerged as a major determinant of lung fibrosis progression. Senescent alveolar epithelial cells exhibit sustained DDR signalling and establish SASP that promotes fibroblast activation and ECM deposition.¹¹¹ Thus, disease outcome is critically influenced by the ability of lung cells to repair DNA lesions in a sustained fashion.

Oxidative stress is a dominant source of lung DNA damage, making BER a key pathway in pulmonary homeostasis. OGG1-mediated repair of 8-oxoG influences inflammatory gene expression, immune cell recruitment and tissue remodelling in the lung.^112,113 In acute injury models, pharmacological inhibition of OGG1 using TH5487 reduced pro-inflammatory gene transcription, attenuated fibroblast activation and decreased collagen deposition in bleomycin-treated mice.¹¹⁴ These findings provided compelling proof that DNA repair pathways can modulate pulmonary fibrosis. Nonetheless, they are best interpreted in the context of acute injury and early inflammatory signalling.¹¹⁵ In such settings, suppressing transcriptional amplification reduces inflammatory cascades that would otherwise accelerate tissue damage. However, follow-up mechanistic studies revealed that OGG1 inhibition stalls repair at the lesion level, prolonging the presence of oxidized bases and repair intermediates.^9,116,117 While tolerable in the short-term, persistent inhibition under chronic oxidative stress risks the accumulation of lesions, increased replicative stress and epithelial senescence, outcomes associated with progressive fibrosis rather than resolution.

Pulmonary fibrosis in patients is inherently a chronic disease. Repetitive epithelial injury, ongoing oxidative stress, mitochondrial dysfunction and impaired alveolar regeneration create conditions in which DNA damage continuously accumulates. Under these circumstances, suppressing repair activity may transiently reduce inflammatory signalling.¹¹⁴ This approach comes at the cost of leaving the underlying genomic damage unresolved.¹¹⁸ Evidence from telomere biology further supports this view. Short telomeres and impaired telomere repair are strong genetic risk factors for IPF and telomeric DNA damage in alveolar epithelial cells promotes senescence and fibrotic remodelling.¹¹⁹ The Opresko laboratory demonstrated that oxidative base repair at telomeres exacerbates long-term cellular dysfunction, even when acute DNA damage signalling is initially reduced.¹²⁰ These findings argue that an inhibition of DNA damage repair is unlikely to be compatible with long-term lung tissue maintenance.

An emerging alternative strategy is to enhance or rewire DNA repair, enabling lung epithelial cells to clear lesions efficiently and to rapidly terminate DDR signalling before senescence and fibroblast activation arise. Recent studies have demonstrated that OGG1 activity offers the necessary mechanistic plasticity.¹²¹ Small molecules that act as organocatalytic switches (ORCAs) accelerate processing of AP sites and facilitate BER rather than stalling repair.¹²² While this strategy has not yet been tested in lung fibrosis models, the mechanistic profile observed previously directly addresses the root cause of chronic epithelial damage of inefficient lesion resolution under sustained oxidative load.^92,123

Cardiovascular tissues are exposed to continuous mechanical stress, metabolic flux and oxidative injury throughout life. Vascular smooth muscle cells (VSMCs), endothelial cells and cardiomyocytes accumulate DNA damage because of ROS, replication stress and inflammation. Unlike rapidly renewing tissues, cardiovascular cells exhibit limited regenerative capacity.¹²⁴ As a result, failure to adequately repair DNA damage has long-lasting consequences, promoting cellular senescence, clonal dysfunction, inflammation and fibrotic remodelling that together drive cardiovascular disease progression.

Seminal work established that DNA damage induces senescence, which in turn propagates atherosclerosis and vascular aging.⁸ Studies in both human plaques and atherosclerotic mouse models demonstrated accumulation of persistent DNA damage markers, including γH2AX and 53BP1 foci, in VSMCs and endothelial cells. These cells undergo growth arrest and acquire SASP, characterized by secretion of pro-inflammatory cytokines, matrix metalloproteinases (MMPs) and pro-fibrotic factors. Further, VSMC senescence is associated with formation of micronuclei, activation of cGAS–STING and induction of multiple pro-inflammatory cytokines, rendering it a partially mitochondrially controlled process.¹²⁵ The selective removal of senescent cells, or prevention of senescence induction, reduces plaque burden, stabilizes lesions and improves vascular function.^126,127 These findings place DNA damage upstream of inflammation and fibrosis in cardiovascular disease, highlighting repair capacity as a key determinant of tissue integrity.

Oxidative stress is a dominant source of vascular DNA damage, particularly in regions exposed to disturbed flow or metabolic dysfunction. 8-OxoG accumulates in VSMCs and endothelial cells with age and disease, activating BER and downstream DNA damage response signalling.¹²⁸ As such, persistent BER activity sustains DDR signalling, enforcing senescence and SASP output. Recent work demonstrates that OGG1 activity declines in aging vasculature, coinciding with increased oxidative DNA damage and vessel stiffness.⁸ Importantly, genetic manipulation restoring active OGG1 in VSMCs preserves arterial compliance and prevents age-associated ECM remodelling. These observations support the idea that the efficient resolution of oxidative DNA lesions protects vascular structure and function, while dysfunctional repair accelerates fibrotic remodelling.

Cardiovascular tissues are continuously active and rarely experience discrete, self-limited injury. Since DNA damage accumulates chronically, repair inhibition risks accelerating lesion persistence, senescence and functional decline. Indeed, in VSMCs, DNA repair deficiencies promote clonal expansion of dysfunctional cells, plaque instability and fibrotic vessel wall thickening.¹²⁹ Ample evidence has established that replication stress and unresolved DNA damage in VSMCs drive pathological clonal selection rather than regeneration, impairing vessel integrity and increasing disease risk.^125,130 Suppressing DNA repair would thus amplify the very processes that drive cardiovascular pathology. In cardiovascular tissues facilitation rather than inhibition of DNA damage repair is therefore the preferred therapeutic strategy. Indeed, restoring repair competence normalizes expression of ECM-regulating proteins such as Lysyl oxidase (LOX) and WNT1-inducible-signaling pathway protein 2 (WISP2) while suppressing TGF-β signalling and collagen accumulation during vascular aging. These molecular changes translate into measurable improvements in arterial compliance and pulse pressure, strengthening the link between DNA repair efficiency and cardiovascular health.

Mitochondrial dysfunction further amplifies cardiovascular disease progression. Damaged mitochondria release oxidized mtDNA, activating cGAS–STING and NLRP3 signalling pathways in both vascular cells and macrophages.¹³¹ These pathways drive inflammation, endothelial dysfunction and fibrotic remodelling of the vessel wall and myocardium. Because mitochondrial DNA damage arises from chronic metabolic and oxidative stress, mitochondrial repair capacity becomes a second major determinant of cardiovascular health.

As discussed above, it emerges that fibrosis is driven less by the magnitude of DNA damage itself than by an imbalance between damage burden and repair capacity over time. When DNA lesions persist, either in the nucleus or the mitochondria, inflammatory signalling is sustained, cellular senescence is promoted and clonal dysfunction intensifies, converging at the initiation of fibrotic tissue remodelling. Emerging therapeutic strategies therefore increasingly focus on facilitating DNA damage repair, rather than on suppressing downstream inflammatory or fibrotic pathways per se. Although several of the approaches discussed above have demonstrated promising effects in mechanistic and preclinical systems, further validation in fibrosis-specific in vivo models and clinical settings will be required to establish their therapeutic potential.

Nuclear DNA repair pathways, particularly BER, represent a first layer of therapeutic opportunity. Diseases characterized by episodic or acute oxidative injury, such as acute lung injury or transient toxic exposures, may benefit from temporary inhibition of specific glycosylase activities. In these contexts, glycosylase inhibition can dampen inflammatory transcriptional amplification driven by BER intermediates and PARP-dependent signalling. Importantly, such approaches are likely to be beneficial only if repair capacity is subsequently restored or compensated, avoiding the prolonged persistence of lesions. In contrast, chronic fibrotic diseases, including MASH, IPF and atherosclerosis, are defined by sustained oxidative stress and the continuous accumulation of DNA damage. In these settings, facilitation of DNA repair rather than inhibition becomes essential. Strategies under development include enhancing glycosylase activity with approaches covering expressed enzymes,⁴⁹ activators^132,133 or ORCAs.^134,135 The desired benefits for these modalities include increased downstream repair flux, improved chromatin accessibility, maintained NAD⁺ and sirtuin function and the efficient recruitment of repair scaffolds. This is based on recent evidence that sirtuin activity, chromatin plasticity and scaffold availability decline under metabolic stress and with age. As a result, tissues are shifted toward persistent damage signalling, senescence and fibrosis, highlighting the robustness of nuclear repair as both a biomarker and therapeutic target in chronic disease.

In this review, we emphasize oxidative DNA damage and BER because these pathways currently offer the clearest mechanistic and pharmacological opportunities for facilitated repair; however, we also recognize that other lesion classes converge on overlapping pro-inflammatory and pro-fibrotic downstream programs.¹³⁶ As an example, beyond direct modulation of BER enzymes, emerging strategies aim to increase overall somatic DNA repair capacity, for example by targeting transcriptional programs that constrain genome maintenance, such as DREAM complex-dependent repression.³⁷

In parallel, increasing attention is focused on the mitochondrial genome as a driver of chronic inflammation and fibrosis.¹³⁷ Accumulating evidence shows that mtDNA damage and leakage into the cytosol convert metabolic stress into innate immune activation, primarily through cGAS–STING and the NLRP3 inflammasome. This positions mitochondrial genome stability as an important mechanistic regulator of fibrotic disease progression. Thus, enhancing mitochondrial DNA repair capacity has emerged as a promising therapeutic strategy. Boosting mitochondrial OGG1 activity could accelerate removal of 8-oxoG lesions, stabilize mtDNA content and support oxidative phosphorylation.^50,52,53 Similarly, POLG, the sole mitochondrial DNA polymerase, represents a critical bottleneck for both replication and repair. First-in-class small-molecule POLG activators have recently been described and shown to increase mtDNA replication and improve respiratory function in patient-derived cells.⁵⁴ Although fibrosis-specific data are still forthcoming, increased mtDNA copy number and repair capacity should reduce mtDNA fragmentation and release, weaken cGAS–STING activation and attenuate chronic inflammation.

Additional approaches aim to prevent mtDNA release or sensing directly, including pharmacological targeting of cGAS–STING¹³⁸ and NLRP3,¹³⁹ both of which have entered clinical development, as well as improving mitochondrial quality control. Enhancing mitophagy, promoting balanced mitochondrial fusion and fission, stabilizing mitochondrial nucleoids via TFAM,¹⁴⁰ and restoring metabolic cofactors that sustain NAD⁺ (ref. 96 and 141) and SIRT3¹⁴² activity may maintain mtDNA integrity under oxidative stress.

Evidence from different organs reinforces the generality of these principles. In the skin, facilitated DNA repair has been achieved through topical delivery of lesion-specific repair enzymes, enhancement of endogenous BER, stabilization of telomeres and metabolic support. The strategy has already demonstrated safety and efficacy in reducing inflammation, photoaging and fibrotic remodelling. In the lung, where both nuclear and mitochondrial DNA damage contribute to epithelial senescence and innate immune activation, dual support of nuclear and mitochondrial repair pathways may be required to achieve durable anti-fibrotic effects. In the cardiovascular system, DNA damage-induced senescence is established as a major driver of vascular dysfunction, clonal pathology and fibrosis, positioning dysfunctional DNA repair as a root cause rather than a secondary feature of disease. Across these tissues, enhancing DNA repair capacity acts through conserved, complementary mechanisms that prevent premature senescence by resolving lesions before checkpoint activation, reducing senescence-associated secretory phenotypes and paracrine inflammation, preserving functional cellular fitness and clonal balance and maintaining ECM homeostasis to prevent excessive collagen deposition and tissue stiffening.

Taken together, these findings support a conceptual shift from targeted inhibition to coordinated enhancement of both nuclear and mitochondrial DNA repair. A dual-axis approach that combines improved nuclear BER with stabilization of the mitochondrial genome has the potential to maximize genomic integrity, suppress both nuclear and mitochondrial sources of DAMPs and limit the transition from chronic damage to inflammation, senescence and fibrosis.

As tools to modulate DNA repair with greater precision continue to emerge, future therapeutic development will likely move beyond organ-specific symptom control toward upstream restoration of genome maintenance. Within this therapeutic basis, facilitated DNA damage repair may represent a foundational strategy for preventing and reversing fibrotic disease across tissues.

Persistent DNA damage has emerged as a central upstream mechanism that links metabolic stress, ageing, chronic inflammation, cellular senescence and ECM remodelling across organ systems. In this paradigm, fibrosis can be seen as the consequence of dysfunctional nuclear and mitochondrial DNA repair processes that fail to effectively resolve DNA lesions in tissues undergoing sustained injury. This perspective shifts therapeutic development away from the ‘simple’ suppression of inflammation and towards the restoration of genome maintenance as a disease-modifying intervention.

Critically, recent advances in human-relevant experimental systems have accelerated the translational viability of this concept. Patient-derived 3D organotypic and microphysiological cultures now allow for the scalable and direct interrogation of DNA damage repair dynamics in disease-relevant human contexts.¹⁴³ These systems capture key features of tissue fibrosis, such as metabolic stress, mitochondrial dysfunction, pro-inflammatory signaling, cellular senescence and ECM remodeling, and enable quantitative assessments of the flux through DNA damage repair pathways in response to chemical modulation.^144–146 As such, they provide an appealing translational approach that can efficiently test new chemical series and shortlist promising lead candidates, thereby bridging between chemical biology and therapeutic development.

From an industry perspective, DNA damage repair pathways represent a largely untapped space for the development of novel modalities against chronic inflammatory and fibrotic diseases with high first-in-class potential. Particularly, DNA glycosylases offer defined catalytic activities and druggable interfaces that can be selectively tuned rather than globally inhibited. Chemical biology strategies that facilitate repair, such as ORCAs or mitochondrially targeted facilitators of DNA damage repair, enable the suppression of DAMPs, thereby acting upstream of immune activation, cytokine release and fibroblast transdifferentiation. Based on the available evidence and developmental trajectory, we foresee that facilitation of DNA damage repair is poised to become an attractive, clinically applicable strategy for chronic inflammatory and fibrotic diseases across organ systems in the near future.

VML is CEO and shareholder of HepaPredict AB, as well as co-founder and shareholder of Shanghai Hepo Biotechnology Ltd. The other authors declare no competing interests.

The authors acknowledge support by the ERC Consolidator Grant 3DMASH ^101170408, the European Union's Horizon Europe program NEMESIS ^101137405, the Swedish Research Council [2021-02801, 2023-03015 and 2024-03401], the Novo Nordisk Foundation [NNF23OC0085944 and NNF23OC0084420], the SciLifeLab and Wallenberg National Program for Data-Driven Life Science [WASPDDLS22:006], the Åke Wiberg Foundation [M25-0337], the Maximon Longevity Foundation and the Robert Bosch Foundation, Stuttgart, Germany.

This work is a Review article. As such, no original data was generated.